Abstract
Methods: The synthesis of conjugates of flutamide with resorcinarene-PAMAM-dendrimers as well as alkyl and ethyl phenyl chains in the lower part of the macrocycle as a nucleus and diethylenetriamines in the dendritic branches gives the opportunity to obtain conjugates in one step of synthesis with 16 and 64 flutamide moieties in the structure.
Results: The in vitro anticancer studies showed that the conjugates of flutamide are more active than the free flutamide and the flutamide derivatives, thus diminishing the amount of flutamide used. The resorcinarenedendrimer- flutamide conjugates with a high drug payload improve the activity of the drug.
Conclusion: This is important in delivering a sufficient amount of flutamide and suggests that the dendrimer facilitates more of the drug being introduced into cells. It was also observed that the new conjugates are less toxic than the anti-androgens.
Keywords: Dendrimers, conjugates, flutamide, anticancer, apoptosis, anti-androgens.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Anticancer Activity of Resorcinarene-PAMAM-Dendrimer Conjugates of Flutamide
Volume: 18 Issue: 7
Author(s): Luis D. Pedro-Hernández, Elena Martínez-Klimova*, Mark E. Martínez-Klimov, Sandra Cortez-Maya, Ana C. Vargas-Medina, Teresa Ramírez-Ápan, Simón Hernández-Ortega and Marcos Martínez-García
Affiliation:
- Instituto de Fisiologia Celular, Universidad Nacional Autonoma de Mexico, Ciudad Universitaria, Circuito Exterior, Coyoacan, C.P. 04510, Mexico D.F,Mexico
Keywords: Dendrimers, conjugates, flutamide, anticancer, apoptosis, anti-androgens.
Abstract: Methods: The synthesis of conjugates of flutamide with resorcinarene-PAMAM-dendrimers as well as alkyl and ethyl phenyl chains in the lower part of the macrocycle as a nucleus and diethylenetriamines in the dendritic branches gives the opportunity to obtain conjugates in one step of synthesis with 16 and 64 flutamide moieties in the structure.
Results: The in vitro anticancer studies showed that the conjugates of flutamide are more active than the free flutamide and the flutamide derivatives, thus diminishing the amount of flutamide used. The resorcinarenedendrimer- flutamide conjugates with a high drug payload improve the activity of the drug.
Conclusion: This is important in delivering a sufficient amount of flutamide and suggests that the dendrimer facilitates more of the drug being introduced into cells. It was also observed that the new conjugates are less toxic than the anti-androgens.
Export Options
About this article
Cite this article as:
Pedro-Hernández D. Luis , Martínez-Klimova Elena *, Martínez-Klimov E. Mark , Cortez-Maya Sandra , Vargas-Medina C. Ana , Ramírez-Ápan Teresa , Hernández-Ortega Simón and Martínez-García Marcos , Anticancer Activity of Resorcinarene-PAMAM-Dendrimer Conjugates of Flutamide, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (7) . https://dx.doi.org/10.2174/1871520618666171219114532
DOI https://dx.doi.org/10.2174/1871520618666171219114532 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma
Current Gene Therapy Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?
Current Cancer Drug Targets Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Current Medicinal Chemistry Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Phytosynthesized Nanoparticles for Effective Cancer Treatment: A Review
Nanoscience & Nanotechnology-Asia Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Targeting Heat Shock Proteins 70/90 and Proteasome for Cancer Therapy
Current Medicinal Chemistry BTX AgilePulse<sup>TM</sup> System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Current Gene Therapy Cellular Based Cancer Vaccines: Type 1 Polarization of Dendritic Cells
Current Medicinal Chemistry Patent Selections
Recent Patents on Nanotechnology Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Models of Antigen Receptor Activation in the Design of Vaccines
Current Pharmaceutical Design The Use of Intravenous Aminobisphosphonates for the Treatment of Pagets Disease of Bone
Mini-Reviews in Medicinal Chemistry